beta

DNLI

Denali Therapeutics Inc

Chart

Stats

Earnings

News

Splits

Dividends

Earnings

Actual EPS
Consensus EPS
Estimated EPS
Number of Estimates
EPS Surprise

Stats

Summary

denali therapeutics inc. (“denali”) is a biotechnology company focused on the discovery and development of therapies for patients with neurodegenerative diseases, including alzheimer’s disease, parkinson’s disease, als and others. denali was founded by scientists, industry experts and investors who share the vision that recent scientific insights into the genetic causes and biological processes underlying neurodegenerative disease, together with new translational medicine tools, offer an unprecedented opportunity to discover and develop effective medicines. denali is rigorously pursuing a science-driven approach to translational medicine and clinical development. founding investors include fidelity biosciences, arch venture partners, flagship ventures and the alaska permanent fund (represented by crestline investors).

Market Cap: 2.86 Billion

Primary Exchange: NASDAQ

Website: https://www.denalitherapeutics.com

Shares Outstanding: 139 Million

Float: 0

Dividend: 0.0 (0.0%)

Beta: 1.82216897196745

Sector: Manufacturing

Industry: Biological Product (except Diagnostic) Manufacturing

Ethical Flags

Longest drawdown: 1054 trading days

From: 2020-12-22 To: 2024-03-07

Lowest Point:

Prevail Therapeutics Proposes IPO Terms

via: SeekingAlpha at 2019-06-13 07:46:25:000

Quick Take Prevail Therapeutics ( PRVL ) has filed to raise gross proceeds of $125 million from a U.S. IPO, according to an S-1/A registration statement . The firm is developing Adeno-Associated Virus-based [AAV-based] gene therapies for the treatment of serious neurodegenerative diseases… read more...

Denali Therapeutics: Key Catalysts Coming Up For This Neurodegenerative Disease Pioneer

via: SeekingAlpha at 2019-06-12 08:10:47:000

Shares of Denali Therapeutics ( DNLI ) have risen by only 5% since its December 2017 IPO was priced at $18 per share. Year to date, the stock is in the red by about 8%. Given my rekindled interest in the Parkinson space and desire to have more names on the radar that could achieve proof of… read more...

Denali's DNL310 nabs accelerated review status in U.S. for MPS II

via: SeekingAlpha at 2019-06-11 06:58:30:000

The FDA grants Orphan Drug and Rare Pediatric Disease Designation status to Denali Therapeutics' ( DNLI +0.6% ) DNL310 for the treatment of mucopolysaccharidosis II (MPS II), also known as Hunter syndrome , a rare inherited disorder characterized by a large head, excess fluid in the bra… read more...

Ex-Date Payment Date Record Date Declared Date Amount Flag Dividend Type Qualified Indicated
Ex-Date Declared Date Record Date Payment Date Ratio To Factor For Factor
Data provided by IEX Cloud